Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EORTC CLTF 2021 | Pegylated liposomal doxorubicin as maintenance in mycosis fungoides

Pablo Ortiz Romero • 14 Oct 2021
EORTC CLTF 2021
Cutaneous T-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Rare Diseases Pegylated liposomal doxorubicin

Pablo Ortiz Romero, MD, PhD, University Complutense, Hospital 12 de Octubre, Medical School, Institute i+12, Madrid, Spain, talks on the use of pegylated liposomal doxorubicin as maintenance treatment for patients with mycosis fungoides, a subtype of cutaneous T-cell lymphoma (CTCL). Prof. Orbitz reports that pegylated liposomal doxorubicin has shown promise as a maintenance therapy. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

More from Pablo Ortiz Romero

1:05
RESMAIN: resmonistat for CTCL maintenance
Pablo Ortiz Romero • 14 Oct 2021
0:58
Approval of brentuximab vedotin for CD30+ mycosis fungoides
Pablo Ortiz Romero • 14 Oct 2021
1:13
Novel therapies on the horizon for CTCL
Pablo Ortiz Romero • 14 Oct 2021
0:38
Link between blood involvement and HRQoL in CTCL patients receiving mogamulizumab
Pablo Ortiz Romero • 14 Oct 2021

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals